Result of AGM

Deltex Medical Group PLC
04 May 2005

            Deltex Medical Group plc ('Deltex Medical' / 'Company')



                       Results of Annual General Meeting



4th May 2005:  Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
AIM listed haemodynamic monitoring company today held its Annual General
Meeting. The following is a summary of comments made by Nigel Keen, Chairman,
and Andy Hill, Chief Executive Officer.  All resolutions put to shareholders at
the meeting were passed.



Deltex Medical has continued to make progress in Q1 2005 towards its goal of
establishing haemodynamic optimisation, using its CardioQTM blood flow monitor,
as a standard of care for patients undergoing moderate and major surgery and for
those in intensive care.



New clinical trial results announced today from the Freeman Hospital in
Newcastle upon Tyne show that patients treated using the CardioQ during bowel
surgery recovered from their operations both more fully and more quickly.  This
is the eighth prospective randomised controlled clinical trial to assess the
impact of using the CardioQ during or after moderate or major surgery; each of
them has shown statistically significant and substantial clinical and economic
benefits and each new study makes our value proposition to hospitals ever more
compelling.



The operating theatre environment comprises the largest component of our target
market due to the volumes of patients treated and we have established a clear
and substantial first-mover advantage in it.  In intensive care units, which
comprise the second largest element of our target market, doctors have a
widening choice of technologies for monitoring cardiac performance; since
instant detection of changes in patients' haemodynamic status is not always as
crucial to their outcomes as it is in operating theatres, the CardioQ often has
to compete on its other strengths of price, safety and ease of use.  An
independent survey of intensive care units in England and Wales validated our
market leading position both as the most common alternative to long established,
but highly invasive, Pulmonary Artery Catheter devices and as comfortably the
most commonly preferred monitoring solution.



In the UK we have seen consistently higher consumption and sales of disposable
probes for each of the last six months and continue to actively pursue such
growth by providing post-sales clinical training on the installed base.  We also
continue to seek growth through expansion of the installed base with a
particular emphasis on promoting wide-scale usage in targeted hospitals.  Two of
the twenty hospitals we targeted most closely in 2004 purchased the CardioQ
monitors they needed in March and a third bought all but two of the monitors the
doctors need to implement the CardioQ as a standard of care for moderate and
major surgery.  We expect to conclude discussions with a number of the other
seventeen hospitals over the coming months and we are considerably expanding the
number of hospitals we target in this way.



We are pursuing similar 'hospital-wide' approaches in the USA and, with our
distributors, in a number of European countries and expect to be able to report
positive progress over the coming months.  In the meantime there are encouraging
signs of underlying growth in both these territories and also in Latin America
and the Far East.



The growth in the recurring revenue stream combined with cost reduction measures
we took earlier in the year, including a 20% reduction in headcount, means that
the average monthly cash burn has been significantly reduced and is now lower
than at any point in the Company's history.  The Company has growing momentum
and is very well positioned to generate the extra sales growth needed to see it
become profitable.  The Board remains confident that the Company has sufficient
cash and working capital facilities to see it through to profitability.



For further information, please contact:-


Deltex Medical Group plc                                       01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director


Financial Dynamics                                             0207 831 3113
David Yates
Lucy Briggs



Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-



  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works



  • proved that the CardioQ works in a wide range of surgical procedures



  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.






                      This information is provided by RNS
            The company news service from the London Stock Exchange